Harvard Apparatus Regenerative Tech Q1 2025 Update
Ticker: HRGN · Form: 10-Q · Filed: May 14, 2025 · CIK: 1563665
| Field | Detail |
|---|---|
| Company | Harvard Apparatus Regenerative Technology, Inc. (HRGN) |
| Form Type | 10-Q |
| Filed Date | May 14, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, regenerative-technology
TL;DR
**Harvard Apparatus Regenerative Tech Q1 2025: Assets $15.9M, Liabilities $0.3M, Net Loss.**
AI Summary
Harvard Apparatus Regenerative Technology, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported total assets of $15,918,979 and total liabilities of $323,000 for the quarter. Revenue for the period was not explicitly stated but the filing indicates a net loss.
Why It Matters
This filing provides a snapshot of the company's financial health and operational status for the first quarter of 2025, which is crucial for investors to assess performance and future prospects.
Risk Assessment
Risk Level: medium — The company's financial performance and the nature of regenerative technology present inherent risks.
Key Numbers
- $15.9M — Total Assets (As of March 31, 2025)
- $0.3M — Total Liabilities (As of March 31, 2025)
- 60,000,000 — Authorized Shares (Common stock authorized)
Key Players & Entities
- Harvard Apparatus Regenerative Technology, Inc. (company) — Filer of the 10-Q
- Biostage, Inc. (company) — Former company name
- March 31, 2025 (date) — End of reporting period
- $15,918,979 (dollar_amount) — Total assets as of March 31, 2025
- $323,000 (dollar_amount) — Total liabilities as of March 31, 2025
FAQ
What was the net income or loss for the quarter ending March 31, 2025?
The filing indicates a net loss for the period, though the exact figure is not explicitly detailed in the provided snippet.
What is the company's primary business activity?
The company is in the Surgical & Medical Instruments & Apparatus industry, with a focus on regenerative technology.
What were the company's retained earnings as of December 31, 2024?
Retained earnings as of December 31, 2024, were not explicitly stated in the provided snippet.
What is the company's principal executive office address?
The principal executive office is located at 84 October Hill Road, Suite 11, Holliston, MA 01746.
When did the company change its name from Biostage, Inc.?
The company changed its name from Biostage, Inc. on March 31, 2016.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 14, 2025 regarding Harvard Apparatus Regenerative Technology, Inc. (HRGN).